APPENDIX 1. ADDITIONAL ENROLLMENT CRITERIA


Exclusion Criteria

Patients with a history of solid organ transplantation, major surgery within 4 weeks, radiation therapy within 2 weeks, or checkpoint inhibitor therapy were excluded. Patients with an active autoimmune disease, immunodeficiency (including HIV infection), or undergoing systemic steroid therapy (daily dose >10 mg) or immunosuppressive therapy within 7 days before treatment were also excluded. Patients with active central nervous system metastases, psychiatric or substance abuse disorders, or history of pneumonitis or hepatitis were ineligible for the study.

APPENDIX 2. STUDY PROCEDURES

PD-L1 expression was measured in formalin-fixed paraffin-embedded samples using the PD-L1 IHC 22C3 pharmDx assay (Agilent) and characterized using CPS (defined as the ratio of number of tumor cells, lymphocytes, and macrophages expressing PD-L1 to the total number of viable tumor cells in the biopsy specimen multiplied by 100). Sarcomatoid differentiation was evaluated by a local pathologist and captured in the electronic database.

SUPPLEMENTARY FIG S1. Patient disposition. nccRCC, non-clear cell renal cell carcinoma.



SUPPLEMENTARY TABLE S1. Kaplan-Meier Estimates for Duration of Response and Survival Outcomes by Patient

Subgroups

	RCC Histology			PD-L1 Status		IMDC Category		
	Papillary n = 118	Chromophobe n = 21	Unclassified n = 26	CPS <1 n = 58	CPS ≥1 n = 102	Favorable n = 53	Intermediate/ Poor n = 112	Sarcomatoid Differentiation n = 38
Response duration								
Patients with response, n	34	2	8	7	36	17	27	16
Median DOR,	29.0	NR	NR	9.5	29.0	11.0	29.0	15.3
months (range) ^a	(2.8 to 31.6+)	(4.2 to 15.0+)	(2.8+ to 26.3+)	(2.8 to 26.0+)	(2.8+ to 31.6+)	(2.8 to 27.7+)	(2.8 to 31.6+)	(2.8+ to 29.5+)
PFS								

Median, months	5.5	3.9	2.8	3.7	5.6	5.3	4.0	6.9
(95% CI) ^a	(3.9 to	(2.6 to 6.9)	(2.8 to 5.1)	(2.8 to	(2.9 to 8.3)	(2.9 to 8.2)	(2.8 to 6.2)	(2.8 to 15.4)
	6.9)			4.2)				
12-month PFS, %	25.5	24.1	22.0	13.0	32.4	22.7	25.8	35.5
(95% CI) ^a	(17.8 to	(8.2 to 44.4)	(8.4 to 39.5)	(5.5 to	(23.3 to	(12.4 to	(17.8 to 34.5)	(20.1 to 51.2)
	33.9)			23.8)	41.7)	35.0)		
24-month PFS, %	18.7	12.0	22.0	9.7	24.3	16.5	19.8	24.8
(95% CI) ^a	(12.0 to	(1.1 to 37.9)	(8.4 to 39.5)	(3.2 to	(16.2 to	(7.8 to	(12.6 to 28.3)	(11.6 to 40.6)
	26.5)			20.7)	33.4)	28.0)		
OS								
Median OS, months	31.5	23.5	17.6	26.6	30.0	NR	24.5	25.5
(95% CI) ^a	(25.5 to	(9.3 to NR)	(7.5 to NR)	(19.2 to	(22.9 to	(30.4 to	(16.7 to 30.0)	(13.1 to 30.0)
	NR)			NR)	NR)	NR)		
12-month OS, %	77.8	71.4	53.8	70.7	74.4	92.5	64.1	68.4
(95% CI) ^a	(69.2 to	(47.2 to 86.0)	(33.3 to 70.6)	(57.2 to	(64.7 to	(81.1 to	(54.4 to 72.2)	(51.1 to 80.7)
	84.3)			80.6)	81.8)	97.1)		

24-month OS, %	64.1	47.6	41.7	55.2	60.2	75.4	50.3	52.6
(95% CI) ^a	(54.7 to	(25.7 to 66.7)	(22.7 to 59.6)	(41.5 to	(50.0 to	(61.5 to	(40.7 to 59.2)	(35.8 to 67.0)
	72.1)			66.9)	69.1)	84.9)		

Abbreviations: DOR, duration of response; CI, confidence interval; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NR, not reached; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free-survival; RCC, renal cell carcinoma.

^aBased on product-limit (Kaplan-Meier) method for censored data.

Supplementary Table S2. Treatment-related Adverse Events Leading to Discontinuation

Adverse event	Patients discontinuing treatment due to a treatment-related					
	adverse event (n=16)					
	No. of patients	Percentage				
Any treatment-related AE leading to treatment	16	9.7				
discontinuation						
Myocarditis	2	1.2				
Nephritis	2	1.2				
Acute kidney injury	1	0.6				
Autoimmune hepatitis	1	0.6				
Cardiac arrest	1	0.6				
Colitis	1	0.6				
Hepatotoxicity	1	0.6				
Lipase increased	1	0.6				
Myositis	1	0.6				
Neuritis	1	0.6				

Pneumonitis	1	0.6
Polyarthritis	1	0.6
Proteinuria	1	0.6
Pulmonary sarcoidosis	1	0.6

AE, adverse event.